Manuscript no. HAEMATOL/2011/059246 entitled “Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response”

Authors: Ulrich Jäger, Michael Fridrik, Markus Zeitlinger, Daniel Heintel, Georg Hopfinger, Sonja Burgstaller, Christine Mannhalter, Wilhelm Oberaigner, Edit Porpaczy, Cathrin Skrabs, Christine Einberger, Johannes Drach, Markus Raderer, Alexander Gaiger, Monique Putman, Richard Greil

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:
• Ulrich Jäger, ulrich.jaeger@meduniwien.ac.at

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): “Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 …………………….. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the conception of the study: Ulrich Jäger, Michael Fridrik, Richard Greil

3) Design & Methods. The following authors were responsible for specific investigations (please detail):
• Ulrich Jäger, Michael Fridrik, Georg Hopfinger, Sonja Burgstaller, Cathrin Skrabs, Christine Einberger, Markus Raderer, Johannes Drach, Alexander Gaiger, and Richard Greil were responsible for substantial clinical data analysis
• Markus Zeitlinger, Monique Putman and Christine Einberger were responsible for pharmakokinetic analysis
• Christine Mannhalter was responsible for generation of molecular data
• Wilhelm Oberaigner, Daniel Heintel and Edit Porpaczy were responsible for statistical analysis

4) Results. The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):
• Ulrich Jäger, Michael Fridrik, Wilhelm Oberaigner, Christine Einberger were responsible for Table 1
• Ulrich Jäger, Michael Fridrik, Monique Putman, Christine Einberger, Edit porpaczy were responsible for Table 2
• Ulrich Jäger, Michael Fridrik, Daniel Heintel, Wilhelm Oberaigner were responsible For Table 3
• Markus Zeitlinger, Ulrich Jäger, Monique Putman were responsible for Figure 1A-D
• Daniel Heintel, Ulrich Jäger were responsible for Figure 2A-F

5) Writing the manuscript. The following authors were responsible for writing the manuscript:
• Ulrich Jäger, Michael Fridrik and Richard Greil were responsible for preparing the draft and final versions
• All authors read, improved and approved the final version of the manuscript.
6) Contributors Listed in Acknowledgments:
Michaela Bronhagl assisted in manuscript preparation
Natascha Vydra assisted in study coordination
Veronika Huter assisted in initial study preparation
Hoffmann La Roche provided study drug supply (rituximab) and financial support to the AGMT